Search Results for: eFFECTOR Initiates Dosing of eFT508
Articles
June 6, 2018
eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma June 6, 2018
eFFECTOR Therapeutics, Inc. recently announced that it has dosed the first patient in the Phase 2 expansion portion of its monotherapy trial of eFT508, the company’s oral, small molecule inhibitor of MNK1/2, for the treatment of relapsed, refractory non-germinal center B cell (non-GCB) diffuse large B cell lymphoma (DLBCL).
October 9, 2017
eFFECTOR Initiates Dosing in Phase II Combination Trial October 9, 2017
eFFECTOR Therapeutics, Inc. recently announced it has initiated dosing in a Phase 2 clinical study of eFT508 in combination with...
